Clinical trial

Mechanisms of Ozone-Induced Alterations in Efferocytosis and Phagocytosis

Name
PRO00100375
Description
The purpose of this research study to understand how environmental and genetic factors may be involved in lung function. Healthy Study participants will undergo a 1-day screening that includes a blood draw and breathing testing, return for a two-day series of testing to include blood draw, and brief breathing test before and after an inhaled challenge with either filtered air (FA) or ozone (O3). Participants return the next day for a brief breathing test, a blood draw and a procedure called bronchoscopy performed under conscious sedation to evaluate the lung after the challenge. Participants then return 18 - 20 days later to repeat the two-day series of testing to be challenged with the exposure not received on the first series, (FA or O3). Each visit will take about 3 - 3.5 hours. Follow-up phone calls from the study team will occur at 24 hours after each 2-day test series. Total study duration is about one to one-and a half months.
Trial arms
Trial start
2019-03-19
Estimated PCD
2023-07-26
Trial end
2023-07-27
Status
Completed
Phase
Early phase I
Treatment
Ozone
Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
Arms:
Ozone (O3)
Other names:
O3
Filtered Air
Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
Arms:
Filtered Air (FA)
Size
22
Primary endpoint
change in ozone induced efferocytosis of lung macrophages (ability to clear dead or dying cells)
Baseline, 21 days
Change in ozone induced phagocytosis of lung macrophages (ability to clear debris or bacteria)
Baseline, 21 days
Eligibility criteria
Inclusion Criteria • Individuals between 18-35 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity) Exclusion Criteria * Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years * Pregnant women and women who are presently lactating. * Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks * College and graduate students or employees who are under direct supervision by any of the investigators in this protocol * Alcohol or illicit substance abuse * Chronic cardio/pulmonary respiratory disorders or other medical conditions as determined by the investigator * Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 \< 8 mg/ml) * Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}
Updated at
2024-03-12

1 organization

1 product

1 indication

Organization
Robert Tighe, MD
Product
Ozone
Indication
Healthy